Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug, RSC-1255, for people with advanced solid tumors who can't tolerate other treatments or who have already failed other treatments. The study has two parts: first, they'll determine the best dose of the drug, and then they'll test its safety and effectiveness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
How many sites are hosting this research program?
"Currently, 6 distinct sites are managing this particular trial. These locations span from Nashville to Denver and Los Angeles with additional medical centres located elsewhere. In order to reduce travel obligations, it is best for participants to opt into a site that is closest in proximity."
Has the FDA certified RSC-1255 Dose Escalation for use?
"We at Power rate the safety of RSC-1255 Dose Escalation with a score of 1 due to its Phase 1 status, meaning there is limited clinical evidence supporting both efficacy and safety."
How many participants are required for this research project?
"This clinical trial needs to enroll 134 qualified individuals across multiple sites. Notable locations include Sarah Cannon Tennessee Oncology in Nashville and the Sarah Cannon Research Institute - Health One located in Denver, Colorado."
Are recruitment efforts still underway for this clinical experiment?
"Information available on clinicaltrials.gov reveals that this trial is actively looking for volunteers and has been since February 2021, with their most recent update taking place in October of 2022."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger